These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3373009)

  • 1. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.
    Norris DA; Kissinger RM; Naughton GM; Bystryn JC
    J Invest Dermatol; 1988 Jun; 90(6):783-9. PubMed ID: 3373009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
    Li DG; Hu WZ; Ma HJ; Liu W; Yang QQ; Zhao G
    Mol Med Rep; 2016 Aug; 14(2):1275-82. PubMed ID: 27277530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytolytic antibodies to melanocytes in vitiligo.
    Cui J; Arita Y; Bystryn JC
    J Invest Dermatol; 1993 Jun; 100(6):812-5. PubMed ID: 8496621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo.
    Yu HS; Kao CH; Yu CL
    J Invest Dermatol; 1993 Jun; 100(6):823-8. PubMed ID: 8496622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients.
    Hann SK; Kim HI; Im S; Park YK; Cui J; Bystryn JC
    J Dermatol Sci; 1993 Dec; 6(3):201-5. PubMed ID: 8136318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo.
    Abdel-Naser MB; Krüger-Krasagakes S; Krasagakis K; Gollnick H; Abdel-Fattah A; Orfanos CE
    Pigment Cell Res; 1994 Feb; 7(1):1-8. PubMed ID: 8072943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes.
    Li YL; Yu CL; Yu HS
    J Invest Dermatol; 2000 Dec; 115(6):969-73. PubMed ID: 11121127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smyth chicken melanocyte autoantibodies: cross-species recognition, in vivo binding, and plasma membrane reactivity of the antiserum.
    Searle EA; Austin LM; Boissy YL; Zhao H; Nordlund JJ; Boissy RE
    Pigment Cell Res; 1993 Jun; 6(3):145-57. PubMed ID: 8234200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation.
    Naughton GK; Eisinger M; Bystryn JC
    J Invest Dermatol; 1983 Dec; 81(6):540-2. PubMed ID: 6196421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to detect complement-mediated antibody-dependent cytotoxicity against human orbital tissue cells in the serum of patients with thyroid-associated ophthalmopathy.
    Dillon J; Zhang ZG; Hiromatsu N; Bernard M; Salvi M; Wall JR
    Autoimmunity; 1989; 5(1-2):125-32. PubMed ID: 2519012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for an autoimmune pathogenesis of vitiligo.
    Ongenae K; Van Geel N; Naeyaert JM
    Pigment Cell Res; 2003 Apr; 16(2):90-100. PubMed ID: 12622785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to melanocytes. Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis.
    Howanitz N; Nordlund JL; Lerner AB; Bystryn JC
    Arch Dermatol; 1981 Nov; 117(11):705-8. PubMed ID: 7316530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients.
    Park YK; Kim NS; Hann SK; Im S
    J Dermatol Sci; 1996 Feb; 11(2):111-20. PubMed ID: 8869031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis of melanocytes in vitiligo results from antibody penetration.
    Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S
    J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to normal human melanocytes in vitiligo.
    Naughton GK; Eisinger M; Bystryn JC
    J Exp Med; 1983 Jul; 158(1):246-51. PubMed ID: 6345714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune vitiligo: detection of antibodies to melanin-producing cells.
    Hertz KC; Gazze LA; Kirkpatrick CH; Katz SI
    N Engl J Med; 1977 Sep; 297(12):634-7. PubMed ID: 331108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autoantibodies in vitiligo. Clinical significance].
    Morgan M; Castells A; Ramírez A
    Med Cutan Ibero Lat Am; 1986; 14(2):139-42. PubMed ID: 3528710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo.
    al Badri AM; Foulis AK; Todd PM; Gariouch JJ; Gudgeon JE; Stewart DG; Gracie JA; Goudie RB
    J Pathol; 1993 Feb; 169(2):203-6. PubMed ID: 8095298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune aspects of vitiligo.
    Kemp EH; Waterman EA; Weetman AP
    Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The detection of melanocyte autoantibodies in the Smyth chicken model for vitiligo.
    Austin LM; Boissy RE; Jacobson BS; Smyth JR
    Clin Immunol Immunopathol; 1992 Aug; 64(2):112-20. PubMed ID: 1643744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.